Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day ConferenceGlobeNewsWire • 09/30/24
Allogene Therapeutics (ALLO) Up 6.4% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 09/06/24
Allogene Therapeutics: Cema-Cel Promising Among Innovative CAR T-Cell TherapiesSeeking Alpha • 08/27/24
Allogene Therapeutics Announces Participation in Upcoming Investor ConferencesGlobeNewsWire • 08/08/24
Allogene Therapeutics Reports Second Quarter 2024 Financial Results and Business UpdateGlobeNewsWire • 08/07/24
Allogene Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business UpdateGlobeNewsWire • 07/31/24
Allogene Therapeutics Activates Three Community Cancer Centers as First Sites for the Pivotal Phase 2 ALPHA3 Trial Evaluating Cemacabtagene Ansegedleucel (cema-cel) as First Line (1L) Consolidation Treatment for Patients with Large B-Cell Lymphoma (LBCL)GlobeNewsWire • 07/01/24
Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to RelapseGlobeNewsWire • 06/20/24
Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T ProductsSeeking Alpha • 06/12/24
If You Can Only Buy One Penny Stock in May, It Better Be One of These 3 NamesInvestorPlace • 05/28/24
Insider Buying of These 6 Stocks Surges: Fracking, Boats, a Buyout Candidate24/7 Wall Street • 05/26/24
Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation SummitGlobeNewsWire • 05/23/24
Allogene Therapeutics (ALLO) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research • 05/13/24
Allogene Therapeutics Announces Pricing of $110 million Offering of Common StockGlobeNewsWire • 05/13/24
Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business UpdateGlobeNewsWire • 05/13/24
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business UpdateGlobeNewsWire • 05/06/24
Allogene Therapeutics Awarded Grant from the California Institute for Regenerative Medicine to Advance Development of an Allogeneic CAR T in Renal Cell CarcinomaGlobeNewsWire • 04/26/24
Allogene Therapeutics (ALLO) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 04/24/24